Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Enanta Pharmaceutica (ENTA)

Enanta Pharmaceutica (ENTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 241,229
  • Shares Outstanding, K 21,179
  • Annual Sales, $ 79,200 K
  • Annual Income, $ -133,820 K
  • 60-Month Beta 0.59
  • Price/Sales 3.12
  • Price/Cash Flow N/A
  • Price/Book 1.77
Trade ENTA with:

Options Overview Details

View History
  • Implied Volatility 79.97% ( +10.80%)
  • Historical Volatility 57.45%
  • IV Percentile 56%
  • IV Rank 50.22%
  • IV High 140.06% on 06/25/24
  • IV Low 19.34% on 08/27/24
  • Put/Call Vol Ratio 0.10
  • Today's Volume 11
  • Volume Avg (30-Day) 11
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 307
  • Open Int (30-Day) 248

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -1.16
  • Number of Estimates 4
  • High Estimate -0.70
  • Low Estimate -1.50
  • Prior Year -1.33
  • Growth Rate Est. (year over year) +12.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.26 +1.15%
on 09/18/24
13.43 -15.19%
on 08/29/24
-0.81 (-6.64%)
since 08/16/24
3-Month
11.26 +1.15%
on 09/18/24
17.24 -33.91%
on 07/15/24
-0.44 (-3.72%)
since 06/18/24
52-Week
8.08 +40.97%
on 11/10/23
17.80 -36.01%
on 04/01/24
-1.24 (-9.82%)
since 09/18/23

Most Recent Stories

More News
Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot

Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot

ENTA : 11.39 (-2.23%)
Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot

Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot

ENTA : 11.39 (-2.23%)
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot

Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot

ENTA : 11.39 (-2.23%)
Enanta Pharmaceuticals: Fiscal Q4 Earnings Snapshot

Enanta Pharmaceuticals: Fiscal Q4 Earnings Snapshot

ENTA : 11.39 (-2.23%)
Why Shares of Enanta Pharmaceuticals Are Dropping Tuesday

The company saw a slight revenue decline in its fiscal 2023 third-quarter earnings report.

JEF : 60.78 (-0.08%)
ABBV : 192.94 (-0.26%)
ENTA : 11.39 (-2.23%)
Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot

Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot

ENTA : 11.39 (-2.23%)
Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot

Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot

ENTA : 11.39 (-2.23%)
Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19

Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced topline data from SPRINT ( S ARS-Cov-2...

ENTA : 11.39 (-2.23%)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4:30 p.m. ET

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported financial results for its fiscal second...

ENTA : 11.39 (-2.23%)
Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2023

Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial...

ENTA : 11.39 (-2.23%)

Business Summary

Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown,...

See More

Key Turning Points

3rd Resistance Point 12.33
2nd Resistance Point 12.09
1st Resistance Point 11.74
Last Price 11.39
1st Support Level 11.15
2nd Support Level 10.91
3rd Support Level 10.56

See More

52-Week High 17.80
Fibonacci 61.8% 14.09
Fibonacci 50% 12.94
Fibonacci 38.2% 11.79
Last Price 11.39
52-Week Low 8.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar